Autosomal Recessive Osteopetrosis 7 (AROP-7)

Autosomal recessive osteopetrosis-7 is a severe, infant-onset, osteoclast-poor form of osteopetrosis caused by biallelic pathogenic variants in TNFRSF11A (RANK). Children typically present with very dense bones, bone-marrow failure (pancytopenia), cranial nerve compression (vision/hearing problems), growth failure, and hypogammaglobulinemia. A key management distinction: in TNFRSF11A-deficient (AROP7) disease, allogeneic hematopoietic stem-cell transplantation (HSCT) can re-establish functional, donor-derived osteoclasts and remodel bone; by contrast, TNFSF11 (RANKL) deficiency is usually non-responsive to HSCT. PMC+2hnl.com+2

AROP7 is a genetic bone disease where the body cannot make working “bone-eating” cells (osteoclasts) because the RANK receptor does not work. Without working osteoclasts, old bone is not removed. Bones become unusually thick and heavy, but also fragile inside. The bone marrow space gets crowded, so blood cells (red cells, white cells, platelets) are not made well. This causes anemia, infections, and easy bruising. Thick skull bones can squeeze the optic nerves (vision loss) and hearing nerves. Some children also have low antibodies (hypogammaglobulinemia). If doctors replace the blood-forming system with healthy donor cells (HSCT), the donor cells can make normal osteoclasts again and the bone can remodel over time. Early diagnosis and treatment are important to protect vision, hearing, growth, and blood formation. PMC+1

Autosomal Recessive Osteopetrosis 7 (often shortened to AROP-7 or OPTB7) is a very rare, inherited bone disease. In this condition, bones become abnormally dense and hard, but also fragile. The problem happens because the body does not make or activate enough of a special bone cell called the osteoclast. Osteoclasts normally dig and clean old bone so new bone can form in the right shape. In AROP-7, a gene called TNFRSF11A (also known as RANK) does not work properly. Without good RANK signals, osteoclasts are very few or do not mature, so bone cannot be resorbed. This makes bones thick, but crowded on the inside, which can squeeze the bone marrow and the nerves that pass through the skull. Many babies show signs early in life, such as poor growth, anemia, frequent infections, problems with vision or hearing, and fractures. AROP-7 is also linked with low antibody levels (hypogammaglobulinemia) in some patients because RANK signaling is shared with the immune system. disease-ontology.org+2ScienceDirect+2

---

Other names

• Osteopetrosis, autosomal recessive type 7 (OPTB7; OMIM 612301)

• RANK-related osteoclast-poor osteopetrosis

• TNFRSF11A-associated malignant infantile osteopetrosis
  These names all point to the same disorder caused by mutations in the TNFRSF11A (RANK) gene leading to a severe, osteoclast-poor form of osteopetrosis. disease-ontology.org+1

---

Types

Doctors group osteopetrosis by inheritance, age at onset, and the gene involved. AROP-7 fits in these larger families:

1. By inheritance:

• Autosomal recessive (both parents carry one silent copy). AROP-7 is in this group and is one of the severe, “malignant infantile” forms. Medscape

2. By age and severity:

• Infantile/malignant forms: start in utero or early infancy, with serious problems such as anemia, infections, and nerve compression. AROP-7 usually appears here. Medscape

• Intermediate childhood forms: start later and can be milder. Medscape

• Adult/benign dominant forms: different disease (autosomal dominant), usually milder and not AROP-7. Medscape

3. By gene and mechanism:

• RANK (TNFRSF11A) deficiency → AROP-7: osteoclast-poor disease with possible hypogammaglobulinemia. ScienceDirect+1
  This gene-based grouping helps labs and clinics decide which tests to run and which complications to monitor.

---

Causes

Each “cause” below explains how RANK malfunction in AROP-7 produces specific problems you might see clinically.

1. Defective RANK signaling: Mutations in TNFRSF11A block signals needed to form and activate osteoclasts. Without this pathway, bone resorption fails. disease-ontology.org

2. Osteoclast shortage (“osteoclast-poor”): Too few osteoclasts means old bone is not removed, so bone becomes solid and heavy. NCBI

3. Abnormal bone remodeling: Building continues without proper removal, so bones are dense but poorly shaped and brittle. Medscape

4. Narrow bone marrow cavities: Thick bone squeezes the marrow space, lowering blood cell production and causing anemia and infections. Medscape

5. Nerve tunnel crowding: Overgrown skull bone compresses optic, auditory, and other cranial nerves, harming vision and hearing. Medscape

6. Hypogammaglobulinemia: RANK signaling also supports parts of the immune system; its failure can lower antibody levels, causing recurrent infections. ScienceDirect+1

7. Calcium handling stress: When bone resorption fails, blood calcium can drop at times, leading to muscle spasms or seizures. Medscape

8. Poor tooth eruption: Teeth need bone removal to erupt. In AROP-7, delayed eruption and dental infections are common. Medscape

9. Fragile dense bone: Although dense, the bone lacks normal micro-architecture, so fractures can still happen with minor injury. Medscape

10. Hepatosplenomegaly: When marrow fails, the liver and spleen try to make blood cells, so they enlarge. Medscape

11. Growth failure: Chronic anemia, recurrent infections, and malnutrition from feeding issues slow growth. NCBI

12. Respiratory infections: Low antibodies and low white cells from marrow crowding increase infection risk. NCBI

13. Developmental delay: Vision and hearing loss, chronic illness, and poor nutrition can delay milestones. NCBI

14. Skull base thickening: Extra bone at skull base can cause hydrocephalus or raised intracranial pressure. Medscape

15. Bone pain: High pressure in bone and micro-cracks can cause aches and pain. Medscape

16. Recurrent anemia: Crowded marrow produces fewer red cells, causing pallor, fatigue, and breathlessness. Medscape

17. Thrombocytopenia: Low platelets from marrow failure can cause bruising and bleeding. Medscape

18. Leukopenia: Low white cells further raise infection risk. Medscape

19. Spine and limb deformity: Poor remodeling can cause bowing, scoliosis, and abnormal gait. Medscape

20. Secondary endocrine stress: Chronic illness and malnutrition can disturb puberty and hormone balance. (This is an expected downstream effect in severe, chronic pediatric disease; core mechanism remains RANK-osteoclast failure.) Medscape

---

Symptoms

1. Frequent infections (ears, chest): due to low antibodies and low white cells. NCBI

2. Poor weight gain and short stature: illness and feeding problems slow growth. NCBI

3. Pale skin and tiredness: anemia from crowded bone marrow. Medscape

4. Easy bruising or bleeding: low platelets from marrow failure. Medscape

5. Vision problems (reduced vision, nystagmus, optic atrophy): nerve compression in the skull. Medscape

6. Hearing loss: compression of auditory nerves or middle ear changes. Medscape

7. Bone pain and tenderness: dense bone under pressure. Medscape

8. Fractures after minor injuries: bone is dense but fragile. Medscape

9. Big liver and spleen: the body tries to make blood outside the marrow. Medscape

10. Delayed tooth eruption and dental infections. Medscape

11. Head enlargement or unusual skull shape: thick skull bones. Medscape

12. Seizures or muscle spasms from low calcium. Medscape

13. Developmental delay from illness burden and sensory loss. NCBI

14. Breathlessness with anemia or lung infections. Medscape

15. General weakness and poor exercise tolerance. Medscape

---

Diagnostic tests

A) Physical examination

1. Growth and nutrition check: The clinician measures weight, length/height, and head circumference. In AROP-7, many infants are small for age, and some have a large head from skull thickening. Medscape

2. Eye and nerve exam: Checking pupils, optic discs, and eye movements can show optic nerve damage from bony narrowing. Medscape

3. Hearing screening: Simple bedside tests or formal audiology can detect hearing loss due to nerve compression. Medscape

4. Liver and spleen palpation: The doctor feels the abdomen for enlargement, which hints at blood-making outside the marrow. Medscape

5. Skeletal inspection: Looking for bone pain points, limb bowing, spine curve, and dental eruption delays guides further testing. Medscape

B) Manual/bedside tests

6. Vision screening charts / fixation tests: Age-appropriate vision tools help track visual loss from optic nerve pressure. Medscape

7. Tuning fork hearing tests (Rinne/Weber): Quick checks to see if hearing loss is nerve-related or conductive; both can occur. Medscape

8. Neurologic bedside exam: Reflexes, muscle tone, and cranial nerve function detect nerve compression or raised brain pressure. Medscape

C) Laboratory and pathological tests

9. Complete blood count (CBC): Looks for anemia, low white cells, and low platelets due to marrow crowding. Medscape

10. Peripheral smear: Shows immature cells or stress signs when marrow struggles, and helps rule out other marrow diseases. Medscape

11. Serum calcium, phosphate, alkaline phosphatase, PTH, vitamin D: Helps assess mineral problems; calcium may be low in severe disease. Medscape

12. Immunoglobulin levels (IgG, IgA, IgM): Can be low in AROP-7 due to RANK pathway effects on immune cells. ScienceDirect

13. Infection work-up (CRP, cultures as needed): Frequent infections require targeted testing and treatment. Medscape

14. Bone marrow evaluation (when safe and indicated): May show reduced hematopoiesis and crowded bony trabeculae; done in specialized centers. Medscape

15. Molecular genetic testing of TNFRSF11A: Confirms AROP-7 by finding pathogenic variants; gold standard for diagnosis and family counseling. disease-ontology.org+1

D) Electrodiagnostic tests

16. Visual evoked potentials (VEP): Measures how quickly and strongly the brain responds to visual signals; delayed or small signals suggest optic nerve compression. Medscape

17. Brainstem auditory evoked responses (BAER/ABR): Checks the hearing nerve pathways; abnormalities suggest nerve compression at the skull base. Medscape

E) Imaging tests

18. Skeletal survey (X-rays): Shows “bone-within-bone,” “Erlenmeyer flask” deformity at long-bone ends, and very dense bones throughout. This is a key hallmark of osteopetrosis. Medscape

19. CT or MRI of the skull and orbits: Evaluates narrowed nerve canals, thick skull base, and possible brain or eye nerve compression. MRI is useful for soft tissues and nerves. Medscape

20. DXA (bone density scan): Confirms unusually high bone mineral density, though in osteopetrosis “denser” does not mean “stronger.” Medscape

Non-pharmacological treatments

Each item includes short purpose and mechanism to keep it readable.

1) Early hematopoietic stem-cell transplantation (HSCT) care pathway
Purpose: Offer the only curative route in eligible AROP7.
Mechanism: Donor hematopoietic stem cells engraft; donor-derived monocyte lineage forms functional osteoclasts that resume bone resorption and reopen marrow spaces; hematopoiesis recovers. Timing matters to protect optic nerves before irreversible damage. PMC+1

2) Multidisciplinary surveillance protocol (hematology, endocrinology, neurosurgery, ophthalmology, ENT, dentistry, infectious diseases)
Purpose: Detect complications (pancytopenia, cranial nerve compression, dental disease) early.
Mechanism: Structured monitoring of blood counts, mineral metabolism, cranial nerve function, and dental status per consensus guidance. OUP Academic

3) Ophthalmologic monitoring + optic canal decompression when indicated
Purpose: Preserve vision if optic nerves are compressed.
Mechanism: Objective visual testing (acuity, fields, VEP, OCT) and imaging; if compression is demonstrated and vision declines, surgical decompression of the optic canal can improve or stabilize vision—best when done early. PubMed+2PubMed+2

4) Hearing surveillance and ENT interventions
Purpose: Address conductive/sensorineural issues from skull-base narrowing or Eustachian dysfunction.
Mechanism: Audiometry, tympanostomy as needed; coordinate with skull-base specialists for foraminal stenosis. OUP Academic

5) Dental and maxillofacial care
Purpose: Prevent osteomyelitis and fractures of dense, brittle jaws; plan extractions carefully.
Mechanism: Rigorous dental hygiene, antibiotic prophylaxis for invasive dental work; specialist extraction protocols. OUP Academic

6) Infection prevention & prompt treatment
Purpose: Reduce morbidity from neutropenia/hypogammaglobulinemia.
Mechanism: Vaccination per schedule (no live vaccines if immunocompromised), early cultures, and rapid, guideline-based antibiotics for febrile illness. OUP Academic

7) Transfusion support
Purpose: Treat symptomatic anemia/thrombocytopenia before and after HSCT or when marrow failure is prominent.
Mechanism: Leukoreduced/irradiated products as appropriate; adhere to transfusion thresholds. PMC

8) Physiotherapy & safe mobility training
Purpose: Improve function and reduce fracture risk.
Mechanism: Low-impact strengthening, balance work, fall-prevention strategies, custom orthoses when needed. OUP Academic

9) Endocrine/mineral monitoring
Purpose: Avoid hypo- or hypercalcemia and secondary issues (tetany, nephrocalcinosis).
Mechanism: Regular checks of Ca/P/25-OH-D/PTH; careful dose-adjustments when using vitamin D analogs. Medscape

10) Neurosurgical management of raised ICP/craniosynostosis (selected cases)
Purpose: Protect brain/vision when skull thickening narrows intracranial volume or foramina.
Mechanism: Cranial expansion/decompression procedures selected by a skull-base team; case-by-case due to bleeding risk in very sclerotic bone. Surgical Neurology International

11) Social-nutrition support
Purpose: Correct failure to thrive and feeding issues in infants.
Mechanism: High-calorie feeds, dietitian input, and safe calcium/vitamin D balance. OUP Academic

12) Genetic counseling
Purpose: Clarify recurrence risk (autosomal recessive) and discuss prenatal/early diagnostic options.
Mechanism: Family testing and counseling about TNFRSF11A variants. Alliance of Genome Resources

---

Drug treatments

Important: Only interferon gamma-1b is FDA-labeled for severe malignant osteopetrosis (supportive effect). Most other medications are off-label in AROP7 and should be used by specialists, often as bridges to HSCT or to treat complications.

1) Interferon gamma-1b (ACTIMMUNE®) — FDA-labeled for severe malignant osteopetrosis
Class & Purpose: Immunomodulatory cytokine; labeled to delay disease progression.
Dose/Timing (per label): Subcutaneous; pediatric dosing is weight-based; monitor CBC/LFTs; consult the current label for specifics.
Mechanism: Modulates osteoclast/immune pathways; clinical effect is supportive, not curative.
Key Safety: Flu-like symptoms, hepatic enzyme elevations, CNS effects; follow label warnings/monitoring. FDA Access Data+1

2) Calcitriol (Rocaltrol®) — off-label in AROP7
Class & Purpose: Active vitamin D analog; historically trialed at high doses to stimulate osteoclast activity.
Dose (label for approved uses): Capsules/solution with mcg-level dosing; avoid hypercalcemia; off-label high-dose regimens carry risk.
Mechanism: Up-regulates osteoclast differentiation/activation; evidence is anecdotal/limited and expert guidance advises against high-dose use outside special situations.
Key Safety: Hypercalcemia, nephrocalcinosis; requires close biochemical monitoring. FDA Access Data+2New England Journal of Medicine+2

3) Calcium gluconate (IV) — supportive, off-label for AROP7
Purpose: Treat acute symptomatic hypocalcemia (e.g., tetany, seizures).
Dosing/Label: IV, individualized to severity; slow administration with ECG monitoring; avoid ceftriaxone–calcium co-precipitation risks.
Mechanism/Safety: Raises ionized calcium rapidly; be cautious with cardiac glycosides and renal risk. FDA Access Data

4) Erythropoiesis-stimulating agents (e.g., epoetin alfa) — supportive, off-label in this disease
Purpose: Manage anemia from marrow failure when transfusions are not enough/appropriate.
Label context: Multiple on-label indications (e.g., chemotherapy-induced anemia), not AROP7; use is clinician-directed.
Safety: Hypertension, thrombotic risk—use the lowest effective dose. FDA Access Data

5) Granulocyte colony–stimulating factor (filgrastim) — supportive, off-label in AROP7
Purpose: Boost neutrophils during infections or peri-HSCT.
Label: Indicated for several neutropenia settings; not specific to AROP7.
Safety: Bone pain, splenic effects; follow label monitoring. FDA Access Data

6) Intravenous immune globulin (IVIG) — supportive for hypogammaglobulinemia
Purpose: Reduce infections when IgG is low.
Label: Approved for primary humoral immunodeficiency; selection of product and dosing per immunology.
Safety: Thrombosis, renal dysfunction warnings. U.S. Food and Drug Administration+1

Additional medications are individualized: broad-spectrum antibiotics for febrile neutropenia/invasive infections; anticonvulsants if seizures occur; analgesics and bone-safe anesthetic planning for procedures. These follow standard pediatric/ID/neurology guidance rather than AROP7-specific labels. OUP Academic

---

Dietary molecular supplements

• Vitamin D3 (cholecalciferol) to maintain sufficiency when not using calcitriol; careful targets to avoid hypercalcemia. OUP Academic

• Elemental calcium only if deficient or symptomatic; avoid over-supplementation to reduce nephrocalcinosis risk. Medscape

• Magnesium if low (supports PTH function and calcium balance). OUP Academic

• Phosphate correction (rare; avoid over-correction). OUP Academic

• Protein-energy support for failure to thrive. OUP Academic

For a detailed, 10-item supplement section with dosing ranges and mechanisms, I can expand on request using pediatric-endocrine guidance and product labels where applicable.

---

Immunity-booster / regenerative / “stem-cell” related drugs

• Filgrastim (G-CSF) to raise neutrophils peri-infection or peri-HSCT (off-label in AROP7). FDA Access Data

• IVIG to replace missing antibodies (if hypogammaglobulinemia). U.S. Food and Drug Administration

• Antimicrobial prophylaxis in selected immunodeficient states per ID guidance (agent depends on risk/exposure). OUP Academic

• Vaccination catch-up/avoidance of live vaccines when immunocompromised; coordinate around HSCT. OUP Academic

• Conditioning regimens for HSCT (specialist-planned; not disease-specific labels). PMC

• Supportive hematinics (iron/folate/B12 if deficient) to optimize erythropoiesis. OUP Academic

---

Surgeries/procedures

1. Allogeneic HSCT – curative intent in AROP7; restores osteoclast function. PMC

2. Optic canal decompression – selected, early cases with documented compressive optic neuropathy; can improve or stabilize vision. PubMed+1

3. Cranial expansion/CSF procedures – for raised ICP or craniosynostosis in carefully chosen cases. Surgical Neurology International

4. Orthopedic fracture fixation – individualized; sclerotic bone complicates fixation; prolonged protected weight-bearing is common. ResearchGate

5. Specialist dental extractions – technique and antibiotics to prevent osteomyelitis. OUP Academic

---

Prevention

1. Genetic counseling for families planning more children. Alliance of Genome Resources

2. Early testing of siblings if symptomatic or at risk. rarediseases.info.nih.gov

3. Vaccinations on time; avoid live vaccines if immunocompromised. OUP Academic

4. Rapid treatment of fevers (seek care the same day). OUP Academic

5. Hand hygiene & crowd avoidance during outbreaks. OUP Academic

6. Dental hygiene and regular dentist visits. OUP Academic

7. Safe home & fall prevention to lower fracture risk. OUP Academic

8. Nutrition support for growth with careful calcium/vitamin D balance. Medscape

9. Scheduled ophthalmology & audiology to catch changes early. OUP Academic

10. Specialist referral early for HSCT evaluation at a center with metabolic bone/HSCT expertise. PMC

---

When to see a doctor

• Fever, breathing trouble, or lethargy (possible severe infection). OUP Academic

• New vision/hearing changes, headaches, vomiting, or seizures. PubMed+1

• Unusual bruising, pallor, or bleeding (pancytopenia). PMC

• Painful fractures or bone pain, especially after minor trauma. OUP Academic

• Poor feeding/failure to thrive in infants. OUP Academic

---

What to eat / what to avoid

• Eat: balanced calories/protein; fruits/vegetables; adequate—but not excessive—vitamin D and calcium under clinician guidance. Good hydration. OUP Academic

• Avoid: unmonitored high-dose vitamin D or calcium; very low-calorie diets; contact sports and high-impact activities without specialist clearance. Medscape

---

FAQs

1) Is AROP7 the same as other osteopetrosis types?
No. AROP7 is due to TNFRSF11A (RANK) variants and is osteoclast-poor with frequent low antibodies. Genetics drive prognosis and treatment choices. PMC

2) Can HSCT cure AROP7?
It’s the only intervention that can restore osteoclast function and remodel bone; outcomes are best if done early. PMC

3) Is there any FDA-approved “pill” that cures AROP7?
No. The only FDA-labeled drug in this space is interferon gamma-1b to delay progression in severe malignant osteopetrosis; it is supportive, not curative. FDA Access Data

4) Does calcitriol help?
Old reports used very high doses, but current expert guidance advises against high-dose calcitriol outside select scenarios due to risks and limited benefit. New England Journal of Medicine+1

5) Why do many children have vision loss?
Thickened skull narrows optic canals, compressing optic nerves; early decompression can help selected patients. PubMed

6) Why are infections common?
Bone-marrow failure reduces white cells; some AROP7 patients have hypogammaglobulinemia. PMC

7) Is IVIG useful?
Yes, when IgG levels are low or infections are recurrent—per immunology protocols (product labels exist for primary immunodeficiency). U.S. Food and Drug Administration

8) Can G-CSF be used for low neutrophils?
Sometimes, under specialist care; it’s off-label for AROP7 but labeled for other neutropenia indications. FDA Access Data

9) What labs should be followed?
CBC, calcium, phosphorus, 25-OH-vitamin D, PTH, renal function; more frequently if using calcitriol. Medscape

10) Are fractures common despite “strong” bones?
Yes. The bones are dense but brittle because normal remodeling is impaired. MedlinePlus

11) Can hearing be affected?
Yes—skull-base narrowing and middle-ear issues can reduce hearing. OUP Academic

12) Should families consider genetic testing?
Yes. It confirms diagnosis, guides HSCT decisions, and informs recurrence risk. Alliance of Genome Resources

13) Is denosumab (RANKL inhibitor) helpful?
No—blocking RANKL would worsen an osteoclast-poor state; it is not a therapy for AROP7. (Pathway logic; not recommended by expert consensus.) OUP Academic

14) What’s the role of antibiotics?
Prompt, guideline-based therapy for infections and peri-procedural prophylaxis when indicated (e.g., dental). OUP Academic

15) What determines prognosis?
Genetic subtype, timing/success of HSCT, and prevention/management of neurologic and infectious complications. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 12, 2025.